Poxel SA (POXEL) - Total Liabilities

Latest as of June 2025: €66.41 Million EUR ≈ $77.63 Million USD

Based on the latest financial reports, Poxel SA (POXEL) has total liabilities worth €66.41 Million EUR (≈ $77.63 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Poxel SA to assess how effectively this company generates cash.

Poxel SA - Total Liabilities Trend (2010–2024)

This chart illustrates how Poxel SA's total liabilities have evolved over time, based on quarterly financial data. Check Poxel SA (POXEL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Poxel SA Competitors by Total Liabilities

The table below lists competitors of Poxel SA ranked by their total liabilities.

Company Country Total Liabilities
Steady Safe TBK PT
JK:SAFE
Indonesia Rp186.48 Billion
FN Factory Outlet Public Company Limited
BK:FN
Thailand ฿236.19 Million
Inocycle Technology Tbk PT
JK:INOV
Indonesia Rp682.16 Billion
Compass Gold Corp
V:CVB
Canada CA$1.82 Million
Daesang Corp Preference Shares
KO:001685
Korea ₩2.04 Trillion
Laon People Inc.
KQ:300120
Korea ₩85.45 Billion
Swvl Holdings Corp
NASDAQ:SWVL
USA $17.53 Million
Worldwide Healthcare Trust Plc
LSE:WWH
UK GBX74.17 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Poxel SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Poxel SA market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.26 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.08 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 13.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Poxel SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Poxel SA (2010–2024)

The table below shows the annual total liabilities of Poxel SA from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 €73.87 Million
≈ $86.36 Million
+37.04%
2023-12-31 €53.90 Million
≈ $63.02 Million
+1.79%
2022-12-31 €52.95 Million
≈ $61.91 Million
+13.44%
2021-12-31 €46.68 Million
≈ $54.58 Million
+22.21%
2020-12-31 €38.20 Million
≈ $44.66 Million
+15.19%
2019-12-31 €33.16 Million
≈ $38.77 Million
-33.33%
2018-12-31 €49.73 Million
≈ $58.14 Million
+4.87%
2017-12-31 €47.43 Million
≈ $55.45 Million
+334.37%
2016-12-31 €10.92 Million
≈ $12.76 Million
+23.79%
2015-12-31 €8.82 Million
≈ $10.31 Million
-46.13%
2014-12-31 €16.37 Million
≈ $19.14 Million
-49.27%
2013-12-31 €32.28 Million
≈ $37.73 Million
+310.22%
2012-12-31 €7.87 Million
≈ $9.20 Million
+178.30%
2011-12-31 €2.83 Million
≈ $3.31 Million
+33.66%
2010-12-31 €2.12 Million
≈ $2.47 Million
--

About Poxel SA

PA:POXEL France Biotechnology
Market Cap
$15.75 Million
€13.47 Million EUR
Market Cap Rank
#25735 Global
#428 in France
Share Price
€0.25
Change (1 day)
-2.33%
52-Week Range
€0.22 - €0.78
All Time High
€16.30
About

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more